ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03025789
Previous Study | Return to List | Next Study

Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03025789
Recruitment Status : Recruiting
First Posted : January 20, 2017
Last Update Posted : May 30, 2018
Sponsor:
Collaborator:
Sanofi
Information provided by (Responsible Party):
Drugs for Neglected Diseases

November 11, 2016
January 20, 2017
May 30, 2018
November 2016
November 2019   (Final data collection date for primary outcome measure)
  • Outcome (success or failure) [ Time Frame: 18 months follow up ]
    Success is defined as a cure, according to the criteria adapted from the WHO
  • Outcome (success or failure) [ Time Frame: 12 month follow up ]
    Success is defined as a cure, according to the criteria adapted from the WHO
Same as current
Complete list of historical versions of study NCT03025789 on ClinicalTrials.gov Archive Site
  • Occurrence of grade ≥ 3 adverse events (AEs) including laboratory and haematological abnormalities [ Time Frame: between the first intake of fexinidazole and the end of the observation period or the follow-up period (18 months) for non-serious AEs assessed as related to fexinidazole ]
    AE severity will be graded according to the National Cancer Institute (NCI) Common Toxicity Criteria for AEs (CTCAE), Version 4.03 (13) and, for certain laboratory parameters, modified CTCAE will be used
  • Occurrence of any serious adverse event (SAE) [ Time Frame: between the first intake of fexinidazole and the end of the follow-up period (18 months) ]
  • Pharmacokinetic measure to assess patient compliance [ Time Frame: at Day 11 ]
    Presence of fexinidazole and/or its main metabolites in the blood for PK analyses
  • Outpatients compliance [ Time Frame: at Day 11 ]
    Number of tablets left over and patient's responses to the questionnaire
  • Outpatients compliance [ Time Frame: at Day 11 ]
    Patient's responses to the questionnaire
  • Feasibility of self-management of treatment intake in outpatients [ Time Frame: Day 11 ]
    based on interview and left over tablets at D11
  • questionnaire on acceptability of packaging for outpatients only [ Time Frame: day 0 and day 11 ]
    questionnaire to be completed by patients and caregivers
  • Whole blood concentration of fexinidazole and its metabolites from dry blood spot of inpatients [ Time Frame: day8, day9, day10, 3hour after treatment administration, Day10, 7h15 after treatment administration, Day10, 24h after treatment administration, Day10, 48h after treatment administration ]
    measured by HPLC/MS/MS Bioanalytical method in all patients treated in hospital
Same as current
Not Provided
Not Provided
 
Fexinidazole in Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
An Open-label Study Assessing Effectiveness, Safety and Compliance With Fexinidazole in Patients With Human African Trypanosomiasis Due to T.b. Gambiense at Any Stage
This study evaluates the effectiveness of fexinidazole administered to patients with g-HAT at all stages of the disease. The aim of the present study is to provide additional information on the effectiveness and safety of fexinidazole and to assess its use under conditions as close as possible to those in real life, both in patients treated on an out-patient basis and in the hospital setting, depending on clinical status
Not Provided
Interventional
Phase 3
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
  • Trypanosomiasis, African
  • Sleeping Sickness
  • Trypanosomiasis; Gambian
Drug: Fexinidazole
Tablets of 600 mg Patients with a weight between 20 and 34kg: 1200mg for 4 days, then 600mg for 6 days Patients with a weight of 35kg and above: 1800mg for 4 days, then 1200mg for 6 days
Experimental: Open label arm
children and adults to receive fexinidazole either as inpatients or outpatients.
Intervention: Drug: Fexinidazole
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
174
Same as current
March 2020
November 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or female patient, including breastfeeding or pregnant women in the second or third trimester.
  • ≥ 6 years of age.
  • ≥ 20 kg body weight.
  • Signed Informed Consent Form and Assent Form for patients less than 18 years of age
  • Trypanosomes detected in any body fluid.
  • Physically able to ingest at least one solid meal per day.
  • Able to take oral medication.
  • Karnofsky Performance Status > 40%.
  • Able to comply with the schedule of follow-up visits and with the study constraints.
  • Easily reachable during the out-patient follow-up period.
  • Willing to undergo lumbar punctures.

Exclusion Criteria:

  • Active clinically relevant medical conditions other than HAT that, in the Investigator's opinion, could jeopardise patient safety or interfere with participation in the study, including but not limited to significant liver or cardiovascular diseases, HIV infection, CNS trauma or seizure disorders, coma or altered consciousness not related to HAT.
  • Severe renal or hepatic impairment defined as:

elevated creatinine at > 3 times the upper limit of normal (ULN) elevated ALT, AST or bilirubin at > 3 ULN

  • Severely deteriorated general condition, such as cardiovascular shock, respiratory distress or terminal illness.
  • Any condition (except symptoms of HAT) that compromises ability to communicate with the Investigator as required for completion of the study.
  • Any contraindication to imidazole products (known hypersensitivity to imidazoles).
  • Treatment for HAT within 2 years prior to inclusion.
  • Prior enrolment in the study or prior intake of fexinidazole.
  • Foreseeable difficulty in complying with the schedule of follow-up visits (migrants, refugees, itinerant traders, etc.).

Temporary Non-inclusion Criteria:

  • Recovery period after antimalarial treatment and/or treatment of helminthiasis (at least 3 days).
  • Uncontrolled diabetes or hypertension or any patients requiring clinical stabilisation; wait until appropriate treatment to control the disease has been initiated.
  • First trimester of pregnancy.
  • Traumatic lumbar puncture at Screening i.e. red blood cells visible in CSF; wait for 48 hours before repeating lumbar puncture.

Eligibility Criteria for Out-patient Treatment

  • Accepting to be treated on an out-patient basis;
  • Karnofsky Performance Status > 50%;
  • Good understanding of the method of administration of fexinidazole by the patient and/or caregiver* (checked using a questionnaire at the time of dispensing fexinidazole);
  • Residing close to the investigational centre, i.e. approximately one hour by road and/or boat, during the treatment period**;
  • Easily reachable during the treatment period;
  • No medical or psychiatric contraindications for treatment as out-patient;
  • No pregnancy or breastfeeding;
  • No neurological symptoms.
Sexes Eligible for Study: All
6 Years and older   (Child, Adult, Older Adult)
No
Contact: Antoine Tarral, Dr +41229069260 atarral@dndi.org
Contact: Christelle Perdrieu, PharmD +41229069236 cperdrieu@dndi.org
Congo, The Democratic Republic of the,   Guinea
 
 
NCT03025789
DNDi-FEX-09-HAT
Yes
Not Provided
Not Provided
Drugs for Neglected Diseases
Drugs for Neglected Diseases
Sanofi
Principal Investigator: Victor Kande Betu Kumeso, Dr Ministère de la Santé
Drugs for Neglected Diseases
May 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP